Literature DB >> 18267282

Non-motor symptoms: identification and management.

Sharon Muzerengi1, Donatella Contrafatto, K Ray Chaudhuri.   

Abstract

Non-motor symptoms are an important part of Parkinson's disease (PD) symptoms complex. They cause a significant burden on the quality of life of patients and their carers and remain a major cause of hospitalisation. Treatment of non-motor symptoms can be challenging as these symptoms are often unresponsive to conventional dopaminergic therapy. However, awareness that these symptoms are related to PD is vital as research into treatment and causation will be the cornerstone for delivering a comprehensive modern treatment for PD.

Entities:  

Mesh：

Year:  2007        PMID： 18267282     DOI： 10.1016/S1353-8020(08)70048-8

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN： 1353-8020            Impact factor:   4.891


  13 in total

1.  Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson's Disease.

Authors:  Danúbia Bonfanti Santos; Dirleise Colle; Eduardo Luiz Gasnhar Moreira; Mariana Appel Hort; Marcelo Godoi; Gael Le Douaron; Antonio Luiz Braga; Jamil Assreuy; Patrick Pierre Michel; Rui Daniel Prediger; Rita Raisman-Vozari; Marcelo Farina
Journal:  Mol Neurobiol       Date:  2016-02-06       Impact factor: 5.590

Review 2.  Gene therapy: a viable therapeutic strategy for Parkinson's disease?

Authors:  Alexander L Berry; Thomas Foltynie
Journal:  J Neurol       Date:  2010-10-21       Impact factor: 4.849

3.  Epigenome-wide association study for Parkinson's disease.

Authors:  Kerry Moore; Amy Jayne McKnight; David Craig; Francis O'Neill
Journal:  Neuromolecular Med       Date:  2014-10-11       Impact factor: 3.843

Review 4.  Toxic Feedback Loop Involving Iron, Reactive Oxygen Species, α-Synuclein and Neuromelanin in Parkinson's Disease and Intervention with Turmeric.

Authors:  Zuné Jansen van Rensburg; Shameemah Abrahams; Soraya Bardien; Colin Kenyon
Journal:  Mol Neurobiol       Date:  2021-08-23       Impact factor: 5.590

5.  Move for change part I: a European survey evaluating the impact of the EPDA Charter for People with Parkinson's disease.

Authors:  B R Bloem; F Stocchi
Journal:  Eur J Neurol       Date:  2011-10-04       Impact factor: 6.089

6.  Ceruloplasmin in Parkinson's disease and the nonmotor symptoms.

Authors:  Xuemei Zhao; Ziqiang Shao; Yu Zhang; Fang Liu; Zhibo Liu; Zunjing Liu
Journal:  Brain Behav       Date:  2018-05-07       Impact factor: 2.708

7.  Determinants of diagnostic latency in Chinese people with Parkinson's disease.

Authors:  Ying Wan; Yingying Zhu; Yi Luo; Xun Han; Yongsheng Li; Jing Gan; Na Wu; Anmu Xie; Zhenguo Liu
Journal:  BMC Neurol       Date:  2019-06-11       Impact factor: 2.474

8.  The role of serotonin in sleep disordered breathing associated with Parkinson disease: a correlative [11C]DASB PET imaging study.

Authors:  Irene M Lelieveld; Martijn L T M Müller; Nicolaas I Bohnen; Robert A Koeppe; Ronald D Chervin; Kirk A Frey; Roger L Albin
Journal:  PLoS One       Date:  2012-07-05       Impact factor: 3.240

Review 9.  Early Life Stress, Depression And Parkinson's Disease: A New Approach.

Authors:  Ernest Dallé; Musa V Mabandla
Journal:  Mol Brain       Date:  2018-03-19       Impact factor: 4.041

Review 10.  Outside in: Unraveling the Role of Neuroinflammation in the Progression of Parkinson's Disease.

Authors:  Paulina Troncoso-Escudero; Alejandra Parra; Melissa Nassif; Rene L Vidal
Journal:  Front Neurol       Date:  2018-10-15       Impact factor: 4.003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.